Zai Lab Limited

Zai Lab Limited is a biopharmaceutical company that develops and commercializes oncology, autoimmune, and infectious disease therapies. As a drug developer, its research pipeline inherently involves animal testing for preclinical safety and efficacy studies, a standard industry practice for regulatory approval. The company’s business model is built on bringing novel therapeutics to market, a process that relies on animal data to advance candidates through clinical trials and toward commercialization. While Zai Lab is structured as a holding company, its operating subsidiaries conduct the research and development activities that necessitate animal use.

Cruelty Free Investors flags the company for involvement in animal testing. The available evidence does not specify the scale, species, or internal policies governing Zai Lab’s animal research. Without subsidiary-level disclosure, the precise nature and extent of its animal testing operations are not publicly detailed. This lack of operational transparency places the company under the general animal_exploitation category.